COMP <GO>
RYTM vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RYTM 4
— UNH 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: UNH
LAST: $92.57 (-0.54%) • MKT CAP: $6.41B
options-implied-move
6.80%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | 88.57% | +1.13 | RYTM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | 11.47% | -41.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.82% | 6.48% | -8.30 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 3.14% | -3.24 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 6.46% | +39.34 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 3.12 | +11.21 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.80% | 6.74% | +0.06 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.3 | 56.0 | -5.80 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.33 | +0.63 | RYTM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 17.1x | +15.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.41B | $364.66B | -$358.25B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | UNH REV | RYTM GROSS % | UNH GROSS % | RYTM FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $447.57B | 89.7% | 88.7% | -$116.6M | $16.07B |
| FY 2024 | $130.1M | $400.28B | 89.7% | 88.3% | -$113.9M | $20.70B |
| FY 2023 | $77.4M | $371.62B | 44.0% | 89.6% | -$139.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
UNH // BETA 0.33